Results 141 to 150 of about 506,913 (207)

Unlocking therapeutic potential: Targeting lymphocyte activation Gene-3 (LAG-3) with fibrinogen-like protein 1 (FGL1) in systemic lupus erythematosus. [PDF]

J Transl Autoimmun
Wang B, Zhang B, Wu M, Xu T.
europepmc   +1 more source

Phase I Study of Fianlimab, a Human Lymphocyte Activation Gene-3 (LAG-3) Monoclonal Antibody, in Combination With Cemiplimab in Advanced Melanoma. [PDF]

J Clin Oncol
Hamid O, Lewis KD, Weise A, McKean M, Papadopoulos KP, Crown J, Kim TM, Lee DH, Thomas SS, Mehnert J, Kaczmar J, Lakhani NJ, Kim KB, Middleton MR, Rabinowits G, Spira AI, Yushak M, Mehmi I, Fang F, Chen S, Mani J, Jankovic V, Wang F, Fiaschi N, Brennan L, Paccaly A, Masinde S, Salvati M, Fury MG, Kroog G, Lowy I, Gullo G.   +31 more
europepmc   +1 more source

Calcium signals in lymphocyte activation and disease

Cell Communication and Signaling, 2009
Feske S
doaj   +1 more source

Inhibitory effects of FK506 in combination with CsA on human lymphocyte alloproliferative responses [PDF]

, 1989
Duquesnoy, RJ, Eiras, G, Makowka, L, Starzl, TE, Todo, S, Zeevi, A   +5 more
core  

Soluble lymphocyte activation gene-3 (sLAG3) and CD4/CD8 ratio dynamics as predictive biomarkers in patients undergoing immune checkpoint blockade for solid malignancies. [PDF]

Br J Cancer
Gorgulho J, Roderburg C, Beier F, Bokemeyer C, Brümmendorf TH, Loosen SH, Luedde T.   +6 more
europepmc   +1 more source